Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
4.3M
Short interest
settlement 2026-10-15
3.4
Days to cover
-0.8 days vs prior
66.5%
Short share of volume
2026-10-28
2
Fails to deliver
settlement 2026-09-28
Mon 2 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in VRTX is 4,263,331 shares, down 453,536 shares over the last month. Over the last 48 readings it ranged from 3,512,605 shares (13 December 2024) to 5,753,349 shares (14 March 2025). At the reported average volume of 1.3M shares a day that is 3.4 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/vrtx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 4,263,331 | -5.3% | 1,257,461 | 3.39 |
| 2026-09-30 | 4,503,200 | -4.5% | 1,063,142 | 4.24 |
| 2026-09-15 | 4,716,867 | +1.2% | 938,157 | 5.03 |
| 2026-08-31 | 4,659,749 | +12.4% | 1,032,621 | 4.51 |
| 2026-08-14 | 4,146,973 | +5.2% | 1,343,908 | 3.09 |
| 2026-07-31 | 3,942,936 | -20.9% | 1,318,061 | 2.99 |
| 2026-07-15 | 4,986,691 | +1.0% | 1,607,817 | 3.10 |
| 2026-06-30 | 4,938,472 | +7.0% | 2,454,849 | 2.01 |
| 2026-06-15 | 4,616,968 | +2.8% | 1,209,855 | 3.82 |
| 2026-05-29 | 4,491,490 | +0.7% | 1,406,784 | 3.19 |
| 2026-05-15 | 4,461,773 | +6.9% | 1,224,873 | 3.64 |
| 2026-04-30 | 4,172,829 | -3.8% | 967,590 | 4.31 |
| 2026-04-15 | 4,336,502 | +7.8% | 1,147,800 | 3.78 |
| 2026-03-31 | 4,021,854 | -2.6% | 1,493,484 | 2.69 |
| 2026-03-13 | 4,127,429 | -6.9% | 1,448,625 | 2.85 |
| 2026-02-27 | 4,433,365 | -0.7% | 1,262,692 | 3.51 |
| 2026-02-13 | 4,466,182 | +1.0% | 1,676,321 | 2.66 |
| 2026-01-30 | 4,422,490 | -0.0% | 1,586,405 | 2.79 |
| 2026-01-15 | 4,423,965 | -11.9% | 1,437,372 | 3.08 |
| 2025-12-31 | 5,022,282 | +17.1% | 1,227,594 | 4.09 |
| 2025-12-15 | 4,287,121 | -3.8% | 1,361,317 | 3.15 |
| 2025-11-28 | 4,455,217 | +11.2% | 1,393,814 | 3.20 |
| 2025-11-14 | 4,006,159 | -3.0% | 1,492,462 | 2.68 |
| 2025-10-31 | 4,131,677 | +16.2% | 1,281,366 | 3.22 |
| 2025-10-15 | 3,555,766 | -0.0% | 1,343,866 | 2.65 |
| 2025-09-30 | 3,557,058 | -12.3% | 2,027,132 | 1.75 |
| 2025-09-15 | 4,053,668 | +11.4% | 1,277,924 | 3.17 |
| 2025-08-29 | 3,639,292 | -1.7% | 1,570,284 | 2.32 |
| 2025-08-15 | 3,700,693 | -15.2% | 3,340,013 | 1.11 |
| 2025-07-31 | 4,362,540 | +4.2% | 1,119,318 | 3.90 |
| 2025-07-15 | 4,188,160 | -4.6% | 1,007,188 | 4.16 |
| 2025-06-30 | 4,389,791 | +8.8% | 1,480,514 | 2.97 |
| 2025-06-13 | 4,034,849 | -8.5% | 1,124,521 | 3.59 |
| 2025-05-30 | 4,408,560 | -8.6% | 1,525,051 | 2.89 |
| 2025-05-15 | 4,824,964 | +27.6% | 2,700,418 | 1.79 |
| 2025-04-30 | 3,780,307 | -13.5% | 1,319,341 | 2.87 |
| 2025-04-15 | 4,371,605 | -2.1% | 1,951,981 | 2.24 |
| 2025-03-31 | 4,463,380 | -22.4% | 1,369,986 | 3.26 |
| 2025-03-14 | 5,753,349 | +4.9% | 1,362,654 | 4.22 |
| 2025-02-28 | 5,484,026 | +8.2% | 1,395,128 | 3.93 |
| 2025-02-14 | 5,066,603 | +11.1% | 1,459,354 | 3.47 |
| 2025-01-31 | 4,561,796 | +3.8% | 1,589,768 | 2.87 |
| 2025-01-15 | 4,394,404 | +11.1% | 1,538,051 | 2.86 |
| 2024-12-31 | 3,955,628 | +12.6% | 2,473,678 | 1.60 |
| 2024-12-13 | 3,512,605 | -4.3% | 1,076,276 | 3.26 |
| 2024-11-29 | 3,671,223 | -10.7% | 1,425,519 | 2.58 |
| 2024-11-15 | 4,110,712 | -8.8% | 1,421,813 | 2.89 |
| 2024-10-31 | 4,504,708 | +5.0% | 995,692 | 4.52 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of VRTX volume is 66.5%, up 15.6 points over the last five sessions. Over the last 30 readings it ranged from 29.2% (20 October 2026) to 74.1% (25 September 2026). The latest reading is 12.1 points above the 30-session average of 54.4%, on 471K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 313K | 471K | 66.5% | 144 |
| 2026-10-27 | 159K | 321K | 49.5% | 5 |
| 2026-10-26 | 241K | 437K | 55.3% | 0 |
| 2026-10-23 | 194K | 331K | 58.4% | 41 |
| 2026-10-22 | 350K | 542K | 64.5% | 0 |
| 2026-10-21 | 268K | 526K | 50.9% | 0 |
| 2026-10-20 | 164K | 562K | 29.2% | 0 |
| 2026-10-19 | 156K | 533K | 29.3% | 0 |
| 2026-10-16 | 174K | 435K | 40.1% | 35 |
| 2026-10-15 | 247K | 828K | 29.9% | 57 |
| 2026-10-14 | 335K | 829K | 40.4% | 0 |
| 2026-10-13 | 260K | 440K | 59.0% | 13 |
| 2026-10-12 | 144K | 392K | 36.6% | 0 |
| 2026-10-09 | 170K | 550K | 30.9% | 26 |
| 2026-10-08 | 277K | 652K | 42.5% | 0 |
| 2026-10-07 | 155K | 284K | 54.6% | 0 |
| 2026-10-06 | 154K | 258K | 59.7% | 988 |
| 2026-10-05 | 132K | 221K | 59.5% | 68 |
| 2026-10-02 | 188K | 322K | 58.3% | 10 |
| 2026-10-01 | 253K | 388K | 65.3% | 54 |
| 2026-09-30 | 207K | 338K | 61.3% | 61 |
| 2026-09-29 | 133K | 185K | 71.7% | 669 |
| 2026-09-28 | 149K | 237K | 62.8% | 15 |
| 2026-09-25 | 210K | 283K | 74.1% | 30 |
| 2026-09-24 | 208K | 286K | 72.6% | 13 |
| 2026-09-23 | 255K | 397K | 64.4% | 8 |
| 2026-09-22 | 287K | 500K | 57.3% | 691 |
| 2026-09-21 | 167K | 276K | 60.6% | 5 |
| 2026-09-18 | 199K | 316K | 63.0% | 30 |
| 2026-09-17 | 165K | 253K | 65.1% | 695 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 28 September 2026, the fails-to-deliver balance in VRTX is 2 shares, down 24,617 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (8 April 2026) to 44,303 shares (1 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-28 | 2 | $526.19 | $1K |
| 2026-09-24 | 24,619 | $516.34 | $12.7M |
| 2026-09-17 | 126 | $513.26 | $65K |
| 2026-08-31 | 3 | $541.69 | $2K |
| 2026-08-26 | 1,828 | $552.85 | $1.0M |
| 2026-08-25 | 4,566 | $547.59 | $2.5M |
| 2026-08-24 | 237 | $548.05 | $130K |
| 2026-08-05 | 255 | $478.71 | $122K |
| 2026-07-28 | 608 | $479.00 | $291K |
| 2026-07-22 | 3,256 | $482.00 | $1.6M |
| 2026-07-17 | 102 | $486.03 | $50K |
| 2026-07-16 | 18 | $477.08 | $9K |
| 2026-07-06 | 500 | $528.04 | $264K |
| 2026-07-01 | 44,303 | $496.73 | $22.0M |
| 2026-06-29 | 24 | $491.34 | $12K |
| 2026-06-25 | 3,775 | $475.20 | $1.8M |
| 2026-06-15 | 3,554 | $444.93 | $1.6M |
| 2026-06-12 | 1,170 | $445.04 | $521K |
| 2026-06-09 | 1 | $442.96 | $443 |
| 2026-06-08 | 47 | $446.83 | $21K |
| 2026-06-02 | 601 | $438.40 | $263K |
| 2026-05-07 | 1 | $427.65 | $428 |
| 2026-05-06 | 214 | $424.36 | $91K |
| 2026-05-04 | 14 | $423.92 | $6K |
| 2026-04-24 | 1,290 | $435.10 | $561K |
| 2026-04-23 | 1 | $437.67 | $438 |
| 2026-04-16 | 2,143 | $441.70 | $947K |
| 2026-04-15 | 14 | $444.28 | $6K |
| 2026-04-08 | 1 | $431.86 | $432 |
| 2026-03-30 | 42,186 | $433.07 | $18.3M |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for VRTX in the last 90 days. The most recent filings are listed below. Latest filing: Brennan Daniel J. (Director) on 2026-10-20.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-20 | Brennan Daniel J. | Director | Grant | 795 | $503.47 | $400K | 795 |
| 2026-09-08 | van Grunsven Jasper | EVP, CP and NPPO | Grant | 9K | $0.00 | $0 | 9K |
| 2026-08-28 | Ambrose Kristen | SVP & Chief Accounting Officer | Grant | 5K | $0.00 | $0 | 12K |
| 2026-08-27 | SACHS BRUCE I | Director | Gift | 6K | $0.00 | $0 | 39K |
| 2026-07-21 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Grant | 8K | $0.00 | $0 | 54K |
| 2026-07-21 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Grant | 8K | $0.00 | $0 | 67K |
| 2026-07-02 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sell | 2K | $524.99 | $787K | 45K |
| 2026-07-02 | McKechnie Duncan | EVP, Chief Commercial Officer | Sell | 2K | $519.00 | $800K | 11K |
| 2026-07-01 | Liu Joy | EVP and Chief Legal Officer | Sell | 828 | $502.71 | $416K | 19K |
| 2026-06-26 | Bozic Carmen | EVP and CMO | Sell | 596 | $482.50 | $288K | 15K |
| 2026-06-18 | Bozic Carmen | EVP and CMO | Sell | 1K | $462.17 | $471K | 16K |
| 2026-06-15 | Bozic Carmen | EVP and CMO | Sell | 4K | $450.00 | $1.8M | 17K |
| 2026-06-05 | Bozic Carmen | EVP and CMO | Sell | 2K | $450.00 | $785K | 21K |
| 2026-06-01 | Liu Joy | EVP and Chief Legal Officer | Sell | 828 | $439.91 | $364K | 20K |
| 2026-05-29 | Bozic Carmen | EVP and CMO | Sell | 2K | $450.00 | $888K | 23K |
| 2026-05-15 | Bunnage Mark E. | EVP, Chief Scientific Officer | Sell | 33 | $453.45 | $15K | 7K |
| 2026-05-15 | Bozic Carmen | EVP and CMO | Sell | 1K | $453.45 | $614K | 25K |
| 2026-05-12 | Bozic Carmen | EVP and CMO | Sell | 7K | $450.00 | $3.1M | 26K |
| 2026-05-04 | Bhatia Sangeeta N. | Director | Sell | 318 | $423.73 | $135K | 5K |
| 2026-05-01 | MCKENZIE DIANA | Director | Returned to company | 796 | price not stated in the filing | not stated | 2K |
| 2026-05-01 | Schneider Jennifer | Director | Returned to company | 796 | price not stated in the filing | not stated | 1K |
| 2026-05-01 | Thornberry Nancy | Director | Returned to company | 398 | price not stated in the filing | not stated | 2K |
| 2026-05-01 | Upadhyay Suketu | Director | Returned to company | 796 | price not stated in the filing | not stated | 2K |
| 2026-05-01 | Thornberry Nancy | Director | Grant | 472 | $0.00 | $0 | 3K |
| 2026-05-01 | Schneider Jennifer | Director | Grant | 472 | $0.00 | $0 | 2K |
| 2026-05-01 | MCKENZIE DIANA | Director | Grant | 943 | $0.00 | $0 | 3K |
| 2026-05-01 | Liu Joy | EVP and Chief Legal Officer | Sell | 1K | $425.02 | $469K | 21K |
| 2026-05-01 | Garber Alan M | Director | Grant | 472 | $0.00 | $0 | 7K |
| 2026-05-01 | Bhatia Sangeeta N. | Director | Grant | 943 | $0.00 | $0 | 5K |
| 2026-04-01 | Liu Joy | EVP and Chief Legal Officer | Sell | 978 | $449.17 | $439K | 22K |
| 2026-03-27 | Bozic Carmen | EVP and CMO | Sell | 2K | $450.95 | $1.1M | 33K |
| 2026-03-13 | Bozic Carmen | EVP and CMO | Sell | 2K | $481.79 | $1.1M | 35K |
| 2026-03-11 | McKechnie Duncan | EVP, Chief Commercial Officer | Sell | 3K | $498.42 | $1.3M | 12K |
| 2026-03-04 | McKechnie Duncan | EVP, Chief Commercial Officer | Sell | 2K | $475.30 | $1.2M | 15K |
| 2026-03-02 | Liu Joy | EVP and Chief Legal Officer | Sell | 892 | $495.96 | $442K | 23K |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | 2K | $496.95 | $857K | 98K |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | 6K | $496.16 | $3.0M | 100K |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | 16K | $495.38 | $7.7M | 106K |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | 3K | $494.33 | $1.7M | 122K |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | 3K | $493.29 | $1.2M | 125K |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | 949 | $491.30 | $466K | 128K |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | 3K | $490.54 | $1.3M | 129K |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | 460 | $489.32 | $225K | 131K |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | 3K | $488.27 | $1.6M | 132K |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | 3K | $487.13 | $1.2M | 135K |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | 240 | $482.84 | $116K | 138K |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | 120 | $481.50 | $58K | 138K |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | 400 | $479.75 | $192K | 138K |
| 2026-02-27 | Bozic Carmen | EVP and CMO | Sell | 2K | $480.31 | $1.1M | 38K |
| 2026-02-26 | Ambrose Kristen | SVP & Chief Accounting Officer | Sell | 357 | $483.36 | $173K | 7K |
| 2026-02-25 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sell | 260 | $486.35 | $126K | 47K |
| 2026-02-25 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sell | 2K | $486.35 | $898K | 56K |
| 2026-02-25 | McKechnie Duncan | EVP, Chief Commercial Officer | Sell | 2K | $489.00 | $1.2M | 18K |
| 2026-02-25 | McKechnie Duncan | EVP, Chief Commercial Officer | Sell | 3K | $486.35 | $1.2M | 20K |
| 2026-02-25 | Bunnage Mark E. | EVP, Chief Scientific Officer | Sell | 620 | $486.35 | $302K | 7K |
| 2026-02-25 | Biller Jonathan | EVP and Chief Legal Officer | Sell | 945 | $486.35 | $460K | 14K |
| 2026-02-25 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Sell | 668 | $486.35 | $325K | 18K |
| 2026-02-25 | Ambrose Kristen | SVP & Chief Accounting Officer | Sell | 223 | $486.35 | $108K | 7K |
| 2026-02-24 | WAGNER CHARLES F JR | EVP, CO & FO | Tax withholding | 2K | $485.11 | $846K | 47K |
| 2026-02-24 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Tax withholding | 2K | $485.11 | $789K | 47K |
| 2026-02-24 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Tax withholding | 2K | $485.11 | $736K | 57K |
| 2026-02-24 | McKechnie Duncan | EVP, Chief Commercial Officer | Tax withholding | 873 | $485.11 | $424K | 22K |
| 2026-02-24 | LEIDEN JEFFREY M | Executive Chairman | Tax withholding | 4K | $485.11 | $1.7M | 35K |
| 2026-02-24 | Kewalramani Reshma | CEO & President | Tax withholding | 5K | $485.11 | $2.4M | 138K |
| 2026-02-24 | Bunnage Mark E. | EVP, Chief Scientific Officer | Tax withholding | 582 | $485.11 | $282K | 8K |
| 2026-02-24 | Bozic Carmen | EVP and CMO | Tax withholding | 1K | $485.11 | $705K | 40K |
| 2026-02-24 | Biller Jonathan | EVP and Chief Legal Officer | Tax withholding | 1K | $485.11 | $555K | 15K |
| 2026-02-24 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Tax withholding | 2K | $485.11 | $789K | 19K |
| 2026-02-24 | Ambrose Kristen | SVP & Chief Accounting Officer | Tax withholding | 546 | $485.11 | $265K | 7K |
| 2026-02-19 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sell | 4K | $471.43 | $2.0M | 59K |
| 2026-02-19 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sell | 12K | $470.54 | $5.5M | 63K |
| 2026-02-19 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sell | 7K | $469.61 | $3.4M | 75K |
| 2026-02-19 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sell | 20K | $468.57 | $9.2M | 82K |
| 2026-02-19 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sell | 10K | $467.75 | $4.8M | 102K |
| 2026-02-19 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sell | 2K | $465.80 | $861K | 112K |
| 2026-02-19 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sell | 3K | $465.05 | $1.3M | 114K |
| 2026-02-19 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sell | 920 | $463.91 | $427K | 117K |
| 2026-02-19 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Exercise or conversion | 25K | $187.53 | $4.7M | 118K |
| 2026-02-19 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Exercise or conversion | 23K | $155.57 | $3.7M | 93K |
| 2026-02-18 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sell | 368 | $473.68 | $174K | 49K |
| 2026-02-18 | LEIDEN JEFFREY M | Executive Chairman | Tax withholding | 3K | $483.75 | $1.4M | 38K |
| 2026-02-18 | Bunnage Mark E. | EVP, Chief Scientific Officer | Sell | 1K | $473.68 | $560K | 8K |
| 2026-02-18 | Biller Jonathan | EVP and Chief Legal Officer | Sell | 1K | $473.68 | $589K | 16K |
| 2026-02-18 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Sell | 817 | $473.68 | $387K | 21K |
| 2026-02-18 | Ambrose Kristen | SVP & Chief Accounting Officer | Sell | 638 | $473.68 | $302K | 8K |
| 2026-02-17 | WAGNER CHARLES F JR | EVP, CO & FO | Tax withholding | 2K | $483.75 | $1.1M | 49K |
| 2026-02-17 | WAGNER CHARLES F JR | EVP, CO & FO | Grant | 7K | $0.00 | $0 | 51K |
| 2026-02-17 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sell | 609 | $489.46 | $298K | 49K |
| 2026-02-17 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Tax withholding | 2K | $483.75 | $1.1M | 50K |
| 2026-02-17 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Grant | 6K | $0.00 | $0 | 52K |
| 2026-02-17 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Tax withholding | 2K | $483.75 | $1.0M | 69K |
| 2026-02-17 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Grant | 6K | $0.00 | $0 | 71K |
| 2026-02-17 | McKechnie Duncan | EVP, Chief Commercial Officer | Tax withholding | 1K | $483.75 | $555K | 23K |
| 2026-02-17 | McKechnie Duncan | EVP, Chief Commercial Officer | Grant | 5K | $0.00 | $0 | 24K |
| 2026-02-17 | LEIDEN JEFFREY M | Executive Chairman | Grant | 8K | $0.00 | $0 | 41K |
| 2026-02-17 | Kewalramani Reshma | CEO & President | Tax withholding | 7K | $483.75 | $3.2M | 143K |
| 2026-02-17 | Kewalramani Reshma | CEO & President | Grant | 16K | $0.00 | $0 | 150K |
| 2026-02-17 | Bunnage Mark E. | EVP, Chief Scientific Officer | Sell | 2K | $489.46 | $1.2M | 10K |
| 2026-02-17 | Bunnage Mark E. | EVP, Chief Scientific Officer | Tax withholding | 1K | $483.75 | $537K | 12K |
| 2026-02-17 | Bunnage Mark E. | EVP, Chief Scientific Officer | Grant | 3K | $0.00 | $0 | 13K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON50 Form 144 notices on file for VRTX worth $96.1M at the prices reported; 0 in the last 90 days worth $0. Latest: Tatsis Ourania filed on 2026-07-02 to sell 1,500 shares ($787K) from 2026-07-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-07-02 | Tatsis OuraniaOfficer | 2K | $787K | 0.001% | 2026-07-02 | Fidelity Brokerage Services LLC |
| 2026-07-02 | McKechnie DuncanOfficer | 2K | $800K | 0.001% | 2026-07-02 | Fidelity Brokerage Services LLC |
| 2026-07-01 | Liu JoyOfficer | 828 | $416K | 0.000% | 2026-07-01 | Fidelity Brokerage Services LLC |
| 2026-06-26 | Bozic CarmenOfficer | 596 | $288K | 0.000% | 2026-06-26 | Fidelity Brokerage Services LLC |
| 2026-06-18 | Bozic CarmenOfficer | 1K | $471K | 0.000% | 2026-06-18 | Fidelity Brokerage Services LLC |
| 2026-06-15 | Bozic CarmenOfficer | 4K | $1.8M | 0.002% | 2026-06-15 | Fidelity Brokerage Services LLC |
| 2026-06-05 | Bozic CarmenOfficer | 2K | $785K | 0.001% | 2026-06-05 | Fidelity Brokerage Services LLC |
| 2026-06-01 | Liu JoyOfficer | 828 | $364K | 0.000% | 2026-06-01 | Fidelity Brokerage Services LLC |
| 2026-05-29 | Bozic CarmenOfficer | 2K | $888K | 0.001% | 2026-05-29 | Fidelity Brokerage Services LLC |
| 2026-05-15 | Bunnage Mark E.Officer | 33 | $15K | 0.000% | 2026-05-15 | Fidelity Brokerage Services LLC |
| 2026-05-15 | Bozic CarmenOfficer | 1K | $614K | 0.001% | 2026-05-15 | Fidelity Brokerage Services LLC |
| 2026-05-12 | Bozic CarmenOfficer | 7K | $3.1M | 0.003% | 2026-05-12 | Fidelity Brokerage Services LLC |
| 2026-05-06 | Biller JonathanOfficer | 5K | $2.2M | 0.002% | 2026-05-06 | Fidelity Brokerage Services LLC |
| 2026-05-04 | Bhatia Sangeeta N.Director | 318 | $135K | 0.000% | 2026-05-04 | Fidelity Brokerage Services LLC |
| 2026-05-01 | Liu JoyOfficer | 1K | $469K | 0.000% | 2026-05-01 | Fidelity Brokerage Services LLC |
| 2026-04-01 | Liu JoyOfficer | 978 | $439K | 0.000% | 2026-04-01 | Fidelity Brokerage Services LLC |
| 2026-03-27 | Bozic CarmenOfficer | 2K | $1.1M | 0.001% | 2026-03-27 | Fidelity Brokerage Services LLC |
| 2026-03-13 | Bozic CarmenOfficer | 2K | $1.1M | 0.001% | 2026-03-13 | Fidelity Brokerage Services LLC |
| 2026-03-11 | McKechnie DuncanOfficer | 3K | $1.3M | 0.001% | 2026-03-11 | Fidelity Brokerage Services LLC |
| 2026-03-04 | McKechnie DuncanOfficer | 2K | $1.2M | 0.001% | 2026-03-04 | Fidelity Brokerage Services LLC |
| 2026-03-02 | Liu JoyOfficer | 892 | $442K | 0.000% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-02-27 | Kewalramani ReshmaOfficer, Director | 40K | $19.7M | 0.016% | 2026-02-27 | Fidelity Brokerage Services LLC |
| 2026-02-27 | Bozic CarmenOfficer | 2K | $1.1M | 0.001% | 2026-02-27 | Fidelity Brokerage Services LLC |
| 2026-02-25 | Tatsis OuraniaOfficer | 260 | $126K | 0.000% | 2026-02-25 | Fidelity Brokerage Services LLC |
| 2026-02-25 | Sachdev AmitOfficer | 2K | $898K | 0.001% | 2026-02-25 | Fidelity Brokerage Services LLC |
| 2026-02-25 | McKechnie DuncanOfficer | 5K | $2.4M | 0.002% | 2026-02-25 | Fidelity Brokerage Services LLC |
| 2026-02-25 | Bunnage Mark E.Officer | 620 | $302K | 0.000% | 2026-02-25 | Fidelity Brokerage Services LLC |
| 2026-02-25 | Biller JonathanOfficer | 945 | $460K | 0.000% | 2026-02-25 | Fidelity Brokerage Services LLC |
| 2026-02-25 | Atkinson Edward Morrow IIIOfficer | 668 | $325K | 0.000% | 2026-02-25 | Fidelity Brokerage Services LLC |
| 2026-02-19 | Sachdev AmitOfficer | 59K | $27.5M | 0.023% | 2026-02-19 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Tatsis OuraniaOfficer | 368 | $174K | 0.000% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Bunnage Mark E.Officer | 1K | $560K | 0.000% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Biller JonathanOfficer | 1K | $589K | 0.000% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Atkinson Edward Morrow IIIOfficer | 817 | $387K | 0.000% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-17 | Tatsis OuraniaOfficer | 609 | $298K | 0.000% | 2026-02-17 | Fidelity Brokerage Services LLC |
| 2026-02-17 | Bunnage Mark E.Officer | 2K | $1.2M | 0.001% | 2026-02-17 | Fidelity Brokerage Services LLC |
| 2026-02-17 | Biller JonathanOfficer | 2K | $1.2M | 0.001% | 2026-02-17 | Fidelity Brokerage Services LLC |
| 2026-02-17 | Atkinson Edward Morrow IIIOfficer | 2K | $994K | 0.001% | 2026-02-17 | Fidelity Brokerage Services LLC |
| 2026-02-13 | Tatsis OuraniaOfficer | 2K | $750K | 0.001% | 2026-02-13 | Fidelity Brokerage Services LLC |
| 2026-02-13 | Biller JonathanOfficer | 988 | $493K | 0.000% | 2026-02-13 | Fidelity Brokerage Services LLC |
| 2026-02-13 | Bhatia Sangeeta N.Director | 266 | $133K | 0.000% | 2026-02-13 | Fidelity Brokerage Services LLC |
| 2026-02-11 | Tatsis OuraniaOfficer | 466 | $215K | 0.000% | 2026-02-11 | Fidelity Brokerage Services LLC |
| 2026-02-11 | Bunnage Mark E.Officer | 2K | $931K | 0.001% | 2026-02-11 | Fidelity Brokerage Services LLC |
| 2026-02-11 | Biller JonathanOfficer | 2K | $886K | 0.001% | 2026-02-11 | Fidelity Brokerage Services LLC |
| 2026-02-11 | Atkinson Edward Morrow IIIOfficer | 2K | $806K | 0.001% | 2026-02-11 | Fidelity Brokerage Services LLC |
| 2026-01-07 | Tatsis OuraniaOfficer | 5K | $2.1M | 0.002% | 2026-01-07 | Fidelity Brokerage Services LLC |
| 2026-01-06 | WAGNER CHARLES F JROfficer | 10K | $4.4M | 0.004% | 2026-01-06 | Fidelity Brokerage Services LLC |
| 2025-12-03 | WAGNER CHARLES F JROfficer | 7K | $3.2M | 0.003% | 2025-12-03 | Fidelity Brokerage Services LLC |
| 2025-12-03 | WAGNER CHARLES F JROfficer | 7K | $3.2M | 0.003% | 2025-12-03 | Fidelity Brokerage Services LLC |
| 2025-12-03 | Tatsis OuraniaOfficer | 5K | $2.0M | 0.002% | 2025-12-03 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON3 holders report 5% or more of VRTX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Capital World Investors at 10.1% of the class (25,695,015 shares), filed 2026-05-14 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-14 | 13G/Ano. 4 | Capital World Investorsinvestment adviser | 25.7M | 10.1% | 2026-03-31 |
| 2026-05-14 | 13G/Ano. 2 | Capital Research Global Investorsinvestment adviser | 21.1M | 8.3% | 2026-03-31 |
| 2026-04-30 | 13G | Vanguard Capital Managementinvestment adviser | 19.0M | 7.5% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 11 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding VRTX at their latest 13F. JSON9 of the 30 tracked managers held VRTX at their latest 13F, $1.11B in total at quarter-end prices. AQR Capital Management is the largest at $305.0M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 5 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 616K | $305.0M | 0.11% | +445K |
| Citadel Advisors | 2026-06-30 | 510K | $253.5M | 0.03% | +171K |
| Millennium Management | 2026-06-30 | 468K | $232.7M | 0.08% | +438K |
| Renaissance Technologies | 2026-06-30 | 320K | $159.0M | 0.22% | -102K |
| Two Sigma Investments | 2026-06-30 | 285K | $141.6M | 0.10% | -93K |
| Fisher Asset Management | 2026-06-30 | 24K | $12.2M | 0.00% | -7K |
| Bridgewater Associates | 2026-06-30 | 11K | $5.4M | 0.02% | -2K |
| D. E. Shaw & Co. | 2026-06-30 | 3K | $1.5M | 0.00% | -246K |
| Point72 Asset Management | 2026-06-30 | 3K | $1.3M | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Vertex Pharmaceuticals reported revenue of $3.33B, up 12.5% from the same quarter a year earlier, and net income of $1.10B (4.31 diluted EPS). In FY 2025 it generated $3.63B of operating cash flow and spent $2.02B on buybacks.
- Cash
- $6.14B
- Equity
- $20.25B
- Total assets
- $27.42B
- Shares outstanding
- 253,460,924
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $3.33B | $1.10B | 33.0% | 4.31 |
| Q1 FY 2026 | 2026-03-31 | $2.99B | $1.03B | 34.5% | 4.02 |
| Q4 FY 2025derived | 2025-12-31 | $3.19B | $1.19B | 37.3% | n/a |
| Q3 FY 2025 | 2025-09-30 | $3.08B | $1.08B | 35.2% | 4.20 |
| Q2 FY 2025 | 2025-06-30 | $2.96B | $1.03B | 34.8% | 3.99 |
| Q1 FY 2025 | 2025-03-31 | $2.77B | $646.3M | 23.3% | 2.49 |
| Q4 FY 2024derived | 2024-12-31 | $2.91B | $913.0M | 31.4% | n/a |
| Q3 FY 2024 | 2024-09-30 | $2.77B | $1.05B | 37.7% | 4.01 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $12.00B | $3.95B | $3.63B | $437.6M | $2.02B | n/a |
| FY 2024 | 2024-12-31 | $11.02B | -$535.6M | -$492.6M | $297.7M | $1.18B | n/a |
| FY 2023 | 2023-12-31 | $9.87B | $3.62B | $3.54B | $200.4M | $427.6M | n/a |
| FY 2022 | 2022-12-31 | $8.93B | $3.32B | $4.13B | $204.7M | $0 | n/a |
| FY 2021 | 2021-12-31 | $7.57B | $2.34B | $2.64B | $235.0M | $1.43B | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Vertex Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Vertex Pharmaceuticals (VRTX), SEC CIK 875320, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-28.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-07-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-03.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-20.JSON and CSV
- Company record
- EDGAR filing index for CIK 875320Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- LEVILevi Strauss
- LHLabcorp Holdings
- LHXL3Harris Technologies
- LIILennox International
- LINLinde
- LITELumentum Holdings
- LMTLockheed Martin
- LNGCheniere Energy
- LNTAlliant Energy
- LOWLowe's Companies
- LPLALPL Financial Holdings
- LQDALiquidia
- LRCXLam Research
- LSCCLattice Semiconductor
- LTHLife Time Group Holdings
- LULUlululemon athletica
Datasets
Frequently Asked Questions
How much of VRTX is sold short?
4,263,331 shares were held short at the 2026-10-15 settlement, 3.4 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is VRTX's daily short volume?
On 2026-10-28, 313,015 of the 470,643 VRTX shares reported to FINRA were sold short, 66.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does VRTX have fails to deliver?
The SEC's latest file shows 2 VRTX shares failed to deliver at settlement 2026-09-28. Fails are reported per settlement date and published twice a month with a lag.
Are VRTX insiders buying or selling?
No open-market insider trades were reported for VRTX in the last 90 days. The most recent filings are listed below. Latest filing: Brennan Daniel J. (Director) on 2026-10-20.
Have VRTX insiders filed to sell?
50 Form 144 notices on file for VRTX worth $96.1M at the prices reported; 0 in the last 90 days worth $0. Latest: Tatsis Ourania filed on 2026-07-02 to sell 1,500 shares ($787K) from 2026-07-02.
Who owns 5% or more of VRTX?
3 holders report 5% or more of VRTX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Capital World Investors at 10.1% of the class (25,695,015 shares), filed 2026-05-14 for an event on 2026-03-31.
What did VRTX report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Vertex Pharmaceuticals reported revenue of $3.33B, up 12.5% from the same quarter a year earlier, and net income of $1.10B (4.31 diluted EPS). In FY 2025 it generated $3.63B of operating cash flow and spent $2.02B on buybacks.
Which tracked 13F managers own VRTX?
9 of the 30 tracked 13F managers held VRTX shares at their latest filing, $1.11B in all. The largest: Cliff Asness's AQR Capital Management (616K shares, $305.0M), Ken Griffin's Citadel Advisors (510K shares, $253.5M), Izzy Englander's Millennium Management (468K shares, $232.7M), Renaissance Technologies (320K shares, $159.0M), Two Sigma Investments (285K shares, $141.6M), Ken Fisher's Fisher Asset Management (24K shares, $12.2M). The table above lists all 9.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.